Currently out of the existing stock ratings of Raghuram Selvaraju, 655 are a BUY (93.44%), 42 are a HOLD (5.99%), 4 are a SELL (0.57%).

Raghuram Selvaraju

Work Performance Price Targets & Ratings Chart

Analyst Raghuram Selvaraju works with a stock forecast success ratio of 29.99% fulfilled within 157.25 days on average. Previously, Raghuram Selvaraju worked at HCWAINWRIGHT.

Raghuram Selvaraju’s has documented 1,303 price targets and ratings displayed on 93 stocks. The coverage was on Healthcare, Basic Materials sectors.

Most recent stock forecast was given on AQST, Aquestive Therapeutics at 05-Apr-2024.

Wall Street Analyst Raghuram Selvaraju

Analyst best performing recommendations are on ORMP (ORAMED PHARMACEUTICALS).
The best stock recommendation documented was for MLTX (MOONLAKE IMMUNOTHERAPEUTICS) at 6/21/2023. The price target of $37 was fulfilled within 5 days with a profit of $10.79 (41.17%) receiving and performance score of 82.33.

Average potential price target upside

AMRN Amarin PLC BCPC Balchem CHEK Check Cap Ltd CODX Co-Diagnostics CPRX Catalyst Pharmaceuticals ETON Eton Pharmaceuticals EVOK Evoke Pharma INO Inovio Pharmaceuticals RKDA Arcadia Biosciences SRNE Sorrento Therape ABEO Abeona Therapeutics ADMS Adamas Pharmaceuticals AEZS Aeterna Zentaris ANGN Angion Biomedica Corp AQST Aquestive Therapeutics AYLA Ayala Pharmaceuticals  BBI Brickell Biotech BBIO BridgeBio Pharma BTAI BioXcel Therapeutics BWAY Brainsway Ltd CDXC Chromadex Corp CRDF Cardiff Oncology EQ Equillium EVFM Evofem Biosciences GMAB Genmab AS GRTX Galera Therapeutics ITMR Itamar Medical Ltd KZR Kezar Life Sciences OBSV ObsEva SA OMER Omeros ORMP Oramed Pharmaceuticals RDHL Redhill Biopharma Ltd ADXN Addex Therapeutics Ltd TMBR Timber Pharmaceuticals URGN UroGen Pharma Ltd APTX Aptinyx RAPT RAPT Therapeutics SLGL Sol Gel Technologies Ltd SPRO Spero Therapeutics TALS Talaris Therapeutics GANX Gain Therapeutics VRNA Verona Pharma PLC ADR ADMA ADMA Biologics AVXL Anavex Life Sciences Corp RMTI Rockwell Medical SELB Selecta Biosciences RVPH Reviva Pharmaceuticals Holdings . KRTX Karuna Therapeutics ENTX Entera Bio Ltd ACRS Aclaris Therapeutics ANVS Annovis Bio  AXSM Axsome Therapeutics COCP Cocrystal Pharma ENLV Enlivex Therapeutics Ltd FENC Fennec Pharmaceuticals INDP Indaptus Therapeutics INM InMed Pharmaceuticals MLTX MoonLake Immunotherapeutics ONCT Oncternal Therapeutics PRVB Provention Bio SPRB Spruce Biosciences  STML Stemline Therapeutics TARO Taro Pharmaceutical Industries Ltd ENSC Ensysce Biosciences GLTO Galecto  TRDA Entrada Therapeutics AADI Aadi Bioscience ACOR Acorda Therapeutics BHC Bausch Health Companies BNTX BioNTech SE CDNA Caredx CELC Celcuity LLC CLBS Caladrius Biosciences CRMD CorMedix PLX Protalix Biotherapeutics REPL Replimune Group RGEN Repligen RGLS Regulus Therapeutics RVMD Revolution Medicines IMMU Immunomedics IMUX Immunic IRWD Ironwood Pharmaceuticals KALA Kala Pharmaceuticals SRTS Sensus Healthcare SWTX SpringWorks Therapeutics SYBX Synlogic TCRR Tcr2 Therapeutics OCUL Ocular Therapeutix ORIC Oric Pharmaceuticals  VIE Viela Bio VYNT Vyant Bio XRAY Dentsply Sirona NBSE NeuBase Therapeutics

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Sell

4 months 24 days ago

1/3 (33.33%)

$-0.04 (-0.99%)

300

Hold

1

$-0.07 (-6.54%)

5

5 months 19 days ago

4/21 (19.05%)

$0.29 (40.85%)

32

Sell

1

$-0.07 (-6.54%)

3.5

8 months 25 days ago

8/11 (72.73%)

$-0.08 (-7.41%)

55

Hold

1.25

$0.18 (16.82%)

2

8 months 25 days ago

2/5 (40%)

$0.17 (15.74%)

215

Buy

10

1 years 9 months 22 days ago

13/47 (27.66%)

$6.81 (213.48%)

194

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Raghuram Selvaraju is most bullish on?

Potential upside of $117.89 has been obtained for AXSM (AXSOME THERAPEUTICS)

Which stock is Raghuram Selvaraju is most reserved on?

Potential downside of -$17.79 has been obtained for BCPC (BALCHEM)

What Year was the first public recommendation made by Raghuram Selvaraju?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?